




PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |   |   |
|--|---|---|
| (51) International Patent Classification <sup>7</sup> :<br><b>A61L 27/22, 27/56, 27/46, A61K 38/18</b>   | <b>A1</b>   | (11) International Publication Number: <b>WO 00/45871</b><br>(43) International Publication Date: 10 August 2000 (10.08.00) |
| <p>(21) International Application Number: PCT/US00/03043</p> <p>(22) International Filing Date: 4 February 2000 (04.02.00)</p> <p>(30) Priority Data:<br/>60/118,615 4 February 1999 (04.02.99) US</p> <p>(71) Applicant (for all designated States except US): SDGI HOLDINGS, INC. [US/US]; Suite 508, 300 Delaware Avenue, Wilmington, DE 19801 (US).</p> <p>(72) Inventor; and<br/>(75) Inventor/Applicant (for US only): MCKAY, William, F. [US/US]; 3870 McElrie Cove, Memphis, TN 38133 (US).</p> <p>(74) Agents: GANDY, Kenneth, A. et al.; Woodard, Emhardt, Naughton, Moriarty &amp; McNett, Bank One Center/Tower, Suite 3700, 111 Monument Circle, Indianapolis, IN 46204 (US).</p> | <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b><br/><i>With international search report.<br/>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> |   |

(54) Title: HIGHLY-MINERALIZED OSTEOGENIC SPONGE COMPOSITIONS, AND USES THEREOF



## (57) Abstract

Osteogenic sponge compositions having enhanced osteoinductive properties for use in bone repair are described. The compositions include a quickly resorbable porous carrier, a more slowly resorbed mineral scaffold and an osteogenic factor, preferably a bone morphogenetic protein. The compositions enable increased osteoinductive activity while retaining a reliable scaffold for the formation of new bone at an implant site. Methods for therapeutic use of the compositions are also described.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   | ML | Mali   | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | MN | Mongolia                                     | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MR | Mauritania                                   | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MW | Malawi                                       | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MX | Mexico                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | NE | Niger  | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NL | Netherlands                                  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NO | Norway                                       | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NZ | New Zealand                                  | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | PL | Poland                                       |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CN | China                    | KZ | Kazakhstan                               | RO | Romania                                      |    |                          |
| CU | Cuba                     | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| CZ | Czech Republic           | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DE | Germany                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| DK | Denmark                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |
| EE | Estonia                  |    |  |    |  |    |                          |

- 1 -

## **HIGHLY-MINERALIZED OSTEOGENIC SPONGE COMPOSITIONS, AND USES THEREOF**

5

### **REFERENCE TO RELATED APPLICATION**

This application claims the benefit of U.S. Patent Application  
10 Serial No. 60/118,615 filed February 4, 1999, which is hereby  
incorporated by reference in its entirety.

### **FIELD OF THE INVENTION**

15 The present invention relates generally to osteogenic  
compositions. Specifically, the present invention relates to an  
osteogenic sponge composition effective for the induction of new  
bone growth in animals.

20

### **BACKGROUND OF THE INVENTION**

Bone grafting has been commonly used to augment healing in  
the treatment of a broad range of musculoskeletal disorders. This  
procedure has several disadvantages. If the bone material is  
obtained from donors of the same species, such as an allograft, an  
25 increased risk of disease transmission and immune reaction exists.  
Bone material surgically removed from the patient, known as an  
autograft, is also undesirable because a sufficient amount of  
autogenous bone may not be available and the additional surgery  
necessary to obtain the autograft increases the risk of infection.

30

Due to the need for safer bone graft materials, efforts have been  
directed to finding bone graft substitutes. Candidate compositions  
include collagen and a bioceramic, such as hydroxyapatite, as these

- 2 -

components are the chief structural materials in bone tissue. Bioceramics provide a porous matrix which encourages some new bone growth but, when used in powdered form, give rise to foreign body-giant cell reactions. Other compositions include  
5 demineralized bone powder and collagen. The osteogenic potential of these compositions have been found to be less than satisfactory.

The discovery of osteogenic factors and their application to bone graft substitute compositions has increased the effectiveness of the above-mentioned compositions. Although many preparations  
10 purport to be effective in bone repair in vertebrates, including higher animals such as primates, most of the experimentation done with the compositions have involved lower animals, such as mice and rats.

In light of this background, there remains a need for improved  
15 osteogenic compositions and methods that effectively induce bone growth in higher animals, including primates.

- 3 -

**SUMMARY OF THE INVENTION**

The invention provides in one preferred embodiment an osteogenic sponge composition useful for the induction of new bone growth in a mammal. This composition includes a resorbable sponge matrix material and an osteogenic factor, preferably one that preferably stimulates osteoblasts and osteoclasts, said osteogenic factor incorporated in the sponge matrix material. The resorbable sponge matrix material is desirably a three-  
10 dimensionally stable yet flexible material, facilitating its use as an implant. The osteogenic factor is usually incorporated in an amount that causes an increased rate of resorption of said sponge matrix material in a mammal. The composition also includes a particulate mineral having an average particle diameter of at least  
15 about 0.5 mm embedded in the resorbable sponge matrix material, wherein the particulate mineral present in a weight ratio of at least 4:1 relative to the resorbable sponge matrix material so as to provide a scaffold for bone ingrowth in the presence of the osteogenic factor. More preferred compositions are even more  
20 highly mineralized, for example wherein the particulate mineral is present in a weight ratio of at least about 10:1 relative to the resorbable sponge matrix material. The particulate mineral is desirably formed of a synthetic calcium phosphate ceramic or of bone, especially cortical bone. The osteogenic factor is most  
25 preferably BMP-2 or LMP, or comprises a nucleotide sequence encoding BMP-2 or LMP.

Another embodiment of the present invention provides a method for inducing bone growth in a primate. The method includes a first  
30 step of providing an osteogenic sponge composition having a

- 4 -

resorbable sponge matrix material and an osteogenic factor that stimulates osteoblasts and osteoclasts incorporated in the sponge matrix material in an amount that causes an increased rate of resorption of the sponge matrix material in the primate. Particulate  
5 mineral having an average particle diameter of at least about 0.5 mm is embedded in said resorbable sponge matrix material and present in a weight ratio of at least 4:1 relative to the resorbable sponge matrix material, so as to provide a scaffold for bone ingrowth in the presence of the osteogenic factor. This osteogenic  
10 sponge composition is implanted in the primate in a void in which bone growth is desired, with the osteogenic sponge composition providing a scaffold for a duration sufficient for osteoid ingrowth through the void. Particularly preferred methods involve bone ingrowth to attain spinal fusions in humans.

15

Another preferred embodiment of the invention provides an osteogenic sponge composition effective for the induction of new bone growth in a mammal (especially a primate) that includes

a carrier consisting essentially of a resorbable sponge matrix  
20 with particulate mineral embedded in the resorbable sponge matrix, wherein the particulate mineral is present in an amount constituting at least about 95% by weight of the carrier. An osteogenic factor that stimulates osteoblasts and osteoclasts is incorporated in said carrier.

25

A still further aspect of the invention provides a highly mineralized sponge implant device consisting essentially of a resorbable sponge matrix formed of collagen and having particulate biocompatible mineral embedded within said matrix. In this  
30 embodiment, the device is comprised 1% to 3% by weight of the

- 5 -

collagen and 97% to 99% by weight of the particulate biocompatible mineral. In another inventive feature, an osteogenic factor can be incorporated in such an implant.

5       A further embodiment of the invention provides an interbody spinal fusion device that includes a load bearing member sized for insertion between adjacent vertebrae and any one of the aforementioned compositions retained by the load bearing member. Such fusion devices can be used in inventive interbody spinal  
10   fusion methods mammals, wherein the devices are appropriately implanted to facilitate spinal fusion.

      A particular feature of the present invention relates to the discovery that the inclusion of an osteogenic factor, especially an  
15   osteoblast- and osteoclast-stimulating osteogenic factor, in a resorbable sponge composition causes a substantially accelerated resorption of the sponge. This rapid resorption can diminish or eliminate the capacity of the sponge composition to effectively stimulate and support new bone formation in a void filled with the  
20   sponge composition. This is particularly the case in primates, including humans, in which the rate of new bone formation is relatively slow. Objects of the present invention are to provide osteogenic sponge compositions effective for the induction of bone growth in mammals, particularly primates, including humans, and  
25   related methods and devices. These and other objects and advantages of the present invention will become apparent upon reading the descriptions herein.

- 6 -

**BRIEF DESCRIPTION OF THE FIGURES**

FIGs. 1 and 2 depict a digitized images of computerized tomography (CT) scans of an L4-L5 posterolateral spinal fusions performed on rhesus monkeys as described in Example 5 (top  
5 panels, section through superior transverse processes; middle panels, section through disc space; lower panels, section through inferior transverse processes).



- 7 -

## DESCRIPTION OF THE PREFERRED EMBODIMENTS

For the purposes of promoting an understanding of the principles of the invention, reference will now be made to preferred  
5 embodiments and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended, such alterations and further modifications of the invention, and such further applications of the principles of the invention as illustrated herein, being  
10 contemplated as would normally occur to one skilled in the art to which the invention relates.

As described above, the invention relates in certain aspects to osteogenic sponge compositions effective for the induction of new  
15 bone growth in mammals and methods for inducing bone growth in mammals. The present invention features osteogenic sponge compositions effective for use in primates, wherein the compositions exhibit high osteoinductive potential and provide a lasting mineral scaffold to support bone ingrowth. Such preferred compositions  
20 include a porous, resorbable sponge carrier, such as collagen in sponge form, and an osteogenic factor that stimulates the action of both osteoblasts (which biologically facilitate the formation of bone) and osteoclasts (which biologically facilitate the resorption of bone). In accordance with the present invention, it has been found that the  
25 incorporation of an effective inductive amount of an osteogenic factor, such as a bone morphogenetic protein (BMP), stimulates osteoclasts to such a level that a porous resorbable carrier is quickly resorbed and, in the absence of a high mineral component in the composition, causes the performance of the composition to suffer in  
30 some cases to the extent that the observation of substantial bone

- 8 -

ingrowth is sporadic. Although such non-mineralized sponge compositions may be highly effective for repair of bone defects in lower animals, such as mice, that have a faster bone growth rate, they are less effective in large animals such as primates, including  
5 humans.

Accordingly, a feature of the present invention is the provision of an osteogenic composition in the form of a sponge that includes a substantial amount of a relatively slowly-resorbed mineral  
10 component that remains at the implant site after the carrier has been rapidly resorbed, in order to provide a scaffold for new bone formation that is not prematurely resorbed due to the osteoclastic potentiation by the bone morphogenic protein in the composition. The present invention also provides methods for using such  
15 osteogenic compositions in treatment of bone trauma, disease and defects, for artificial arthrodeses and for other treatment where new bone formation is desired, especially in primates, including humans.

The sponge matrix material is preferably collagenous. A wide  
20 variety of collagen materials are suitable for the sponge matrix. Naturally occurring collagens may be subclassified into several different types depending on their amino acid sequence, carbohydrate content and presence or absence of disulfide cross-links. Types I and III collagen are two of the most common subtypes  
25 of collagen. Type I collagen is present in skin, tendon and bone whereas Type III collagen is found primarily in skin. The collagen in the composition may be obtained from skin, bone, tendon, or cartilage and purified by methods known in the art. Alternatively, the collagen may be purchased commercially. The collagen in the  
30 composition is preferably Type I bovine collagen.

- 9 -

The collagen carrier can further be atelopeptide collagen and/or telopeptide collagen. Moreover, both non-fibrillar and fibrillar collagen may be used. Non-fibrillar collagen is collagen that has  
5 been solubilized and has not been reconstituted into its native fibrillar form.

The sponge carrier may also be formed of other natural or synthetic polymeric materials, in addition to or as an alternative to  
10 collagen. For example, the sponge carrier may be formed of gelatin (e.g. foamed gelatin), in addition collagen or as an alternative to collagen. Other natural and synthetic polymers are also known for the formation of biocompatible sponge materials, and can be used herein.

15

As indicated above, preferred compositions of the invention also include an osteoinductive factor, such as an osteoinductive protein or a nucleotide sequence encoding an osteoinductive protein operably associated with a promoter (e.g. provided in a vector such as a viral  
20 vector) which drives expression of the gene in the animal recipient to produce an effective amount of the protein. The osteogenic factor utilized in the present invention can be one that stimulates production or activity of osteoblasts and osteoclasts. The factor is preferably a bone morphogenetic protein (BMP) or a LIM mineralization protein (LMP), or  
25 comprises a nucleotide sequence encoding a BMP or LMP. Recombinant human BMPs are preferred, and may be commercially obtained or prepared as described and known in the art, e.g. in U.S. Patent Nos. 5,187,076 to Wozney et al.; 5,366,875 to Wozney et al.; 4,877,864 to Wang et al.; 5,108,932 to Wang et al.; 5,116,738 to Wang et al.;  
30 5,013,649 to Wang et al.; 5,106,748 to Wozney et al; and PCT Patent Nos.

- 10 -

WO93/00432 to Wozney et al.; WO94/2693 to Celeste et al.; and WO94/26892 to Celeste et al. Further, the osteoinductive factor may be isolated from bone. Methods for isolating BMP from bone are described in U.S. Patent no. 4,294,753 to Urist and Urist et al., PNAS 371, 1984.

5 Recombinant human BMP-2 (rhBMP-2), recombinant human BMP-4 (rhBMP-4), recombinant human BMP-7 (rhBMP-7) or heterodimers thereof are most preferred. The osteoinductive factor may also be LIM mineralization protein (LMP) or a suitable vector incorporating a gene encoding the same operably associated with a promotor, as described in

10 WO99/06563 (see also genbank accession No. AF095585). When such vectors are employed as osteogenic factors in accordance with the invention, they are preferably delivered in conjunction with cells, for example autologous cells from the recipient of the implant. Most preferably the vector is delivered in conjunction with autologous white

15 blood cells derived from bone marrow or peripheral blood of the recipient. These cells may be applied to the sponge composition along with the osteogenic factor prior to implantation.

The particulate mineral component includes a natural or

20 synthetic mineral that is effective in providing a scaffold for bone ingrowth as the resorbable carrier is resorbed. The mineral may be, for example, bone, especially cortical bone, or a synthetic bioceramic such as a biocompatible calcium phosphate ceramic. Illustrative ceramics include tricalcium phosphate, hydroxyapatite, and

25 biphasic calcium phosphate. These mineral components may be purchased commercially or obtained or synthesized by methods known in the art.

Biphasic calcium phosphate is a particularly preferred

30 synthetic ceramic for use in the invention. Desirably, such biphasic

- 11 -

calcium phosphate with have a tricalcium phosphate:hydroxyapatite weight ratio of about 50:50 to about 95:5, more preferably about 70:30 to about 95:5, even more preferably about 80:20 to about 90:10, and most preferably about 85:15.

5

In general, the amount of mineral in the osteogenic sponge composition must be sufficient to provide a scaffold that will remain in the patient for a period of time sufficient for the formation of osteoid in the void for which bone growth is desired. Typically, this  
10 period of time will be about 6 to about 8 weeks. The minimum level of mineral that must be present in the composition is also dependent on the activity of the BMP in the composition; the higher the activity of the BMP, the greater the content of the mineral matrix required to counter the osteoclastic potentiation of the BMP. The  
15 rate of resorption of the resorbable carrier also increases as the BMP concentration increases.

In preferred aspects of the invention, the particulate mineral:resorbable sponge matrix weight ratio will be at least about  
20 4:1, more preferably at least about 10:1. In particularly preferred sponge implants, the particulate mineral will constitute at least 95% by weight of the sponge implant. For example, highly effective sponge carrier devices are provided wherein they comprise about 97% to about 99% by weight particulate mineral and about 1% to  
25 about 3% of the collagen or other sponge-forming matrix material. Moreover, it is preferred that the mineral component have an average particle size of at least about 0.5 mm, more preferably about 0.5 mm to about 5 mm, and most preferably about 1 mm to about 3 mm.

30

- 12 -

To make the sponge implant, a collagen slurry may be formed as known and preferably is chilled to increase its viscosity to help suspend the porous particulate mineral component. The porous particulate mineral is dispersed into the collagen slurry and gently  
5 mixed. After the porous particulate mineral component is uniformly dispersed in the slurry, the slurry is poured into sterile trays or other forms and freeze dried. The sheets of composite sponge are then removed from the freeze drier and exposed to a glutaraldehyde cross-linking agent. The composite sponge formed is generally  
10 three-dimensionally stable and can be sterilized and packaged in accordance with known procedures.

The dimensions of the sponge produced may vary depending on the application. Dimensions of a typical sponge are, for example,  
15 about 10 cm (length) x 7.5 cm (width) x 0.35 cm (height).

As one example, BMP or other osteogenic factors may be included in the formed sponge by combining the BMP with a liquid carrier as known in the art and infusing the liquid into the sponge.

20

As further enhancements of the compositions of the present invention, those skilled in the art will readily appreciate that other osteogenic enhancing factors may be incorporated into the composition. Such additional factors include host compatible  
25 osteogenic progenitor cells, autographic bone marrow, allographic bone marrow, transforming growth factor- $\beta$ , fibroblast growth factor, platelet-derived growth factor, insulin-like growth factor, microglobulin- $\beta$ , antibiotics and steroids.

30 In yet another aspect of the invention, methods for inducing bone

- 13 -

growth in mammals are provided. The methods include providing the above-described osteogenic sponge composition and implanting the composition at a site at which bone growth is desired, e.g., to treat a disease, defect or location of trauma, and/or to promote  
5 artificial arthrodesis. The hydrated sponge composition may be rolled up prior to packing the sponge into the implantation site.

Once in place, the osteogenic sponge composition will effectively induce and support ingrowth of bone into the desired area even in a  
10 primate such as a human that exhibits a relatively slow rate of bone formation compared to smaller mammals, such as rodents or rabbits. Although the collagen carrier is resorbed relatively quickly, the substantial mineral component remains as a scaffolding to support new bone growth in and through the desired area.

15

The above osteogenic sponge compositions of the present invention are especially advantageous when used in bones or bone portions that exhibit only low to moderate vascularization. Such low to moderate vascularized regions exhibit low rates of bone formation  
20 so rapid resorption of a carrier poses a problem. Examples of low to moderate vascularized sites include, for example, transverse processes or other posterior elements of the spine.

An especially preferred use of the sponge compositions of the  
25 present invention is as an implant to promote arthrodesis between vertebrae in spinal fusions in humans or other primates, including interbody, posterior and/or posterolateral fusion techniques. Although the rate of bone formation in the primate spine is relatively slow overall and thus will benefit generally from the  
30 present invention, the elements to be fused in posterior and

posterolateral fusions exhibit particularly low levels of vascularization and thus fusions of these elements are expected to benefit markedly from the invention.

Reference will now be made to specific examples using the processes described above. It is to be understood that the examples are illustrative and not limiting of the invention.

## 20

25



- 15 -

**EXAMPLE 2**  
**PREPARATION OF COLLAGEN SPONGE/  
SYNTHETIC CERAMIC COMPOSITE**

5

12 grams of biphasic calcium phosphate particles, 1 mm in diameter, were added to 12 grams of collagen slurry (0.192 grams of collagen). This composite slurry was poured into a 7.5 cm x 10.0 cm mold, freeze dried, double sterile packaged, and sterilized by ETO gas sterilization.

10

**EXAMPLE 3**  
**PREPARATION OF COLLAGEN SPONGE/  
BONE PARTICLE COMPOSITE**

15

12 grams of deproteinized cortical bone chips, 1-3 mm in size, were added to 24 grams of collagen slurry (0.192 grams of collagen). This composite slurry was poured into a 7.5 cm x 10.0 cm mold, freeze dried, double sterile packaged, and sterilized by ETO gas sterilization.

20

**EXAMPLE 4**  
**PREPARATION OF COLLAGEN SPONGE/  
SYNTHETIC CERAMIC COMPOSITE**

25

12 grams of biphasic calcium phosphate particles, 1 mm in diameter, were added to 24 grams of collagen slurry (0.192 grams of collagen). This composite slurry was poured into a 7.5 cm x 10.0 cm mold, freeze dried, double sterile packaged, and sterilized by ETO gas sterilization.

30

- 16 -

**EXAMPLE 5**  
**L4-L5 POSTEROLATERAL INTERTRANSVERSE PROCESS**  
**SPINAL FUSION STUDY**

5

The present study was performed to determine the effect of the osteogenic sponge compositions of the present invention on spinal fusion.

10 The experimental group included two adult rhesus monkeys (*Macaca mulatta*). The monkeys were anesthetized with 3-5 mg/kg telazol intramuscularly (i.m.). The anesthesia was maintained with 1.5-2.0% isoflurane. After anesthesia was achieved, animals were shaved, prepared with betadine and sterily draped. The surgical site was infiltrated with 10-15 ml of 0.25% marcaine to aid with  
15 immediate postoperative analgesia. A midline posterior skin incision was made over the lumbar spine. The paraspinal muscles were reflected using elevators, exposing the lamina and the transverse processes of the L4 and L5 vertebral bodies. The transverse processes of the two vertebrae to be fused were decorticated with an  
20 electric burr.

Composite sponges, having dimension of 3.5 cm x 1.4 cm x 0.35 cm, were prepared using techniques as described in Examples 1 and 2. The sponges included, on a weight basis, 97% biphasic calcium phosphate (15% hydroxyapatite and 85% tricalcium  
25 phosphate, 1 mm particle size) and 3% collagen. Recombinant human BMP-2 (rhBMP-2) was prepared at a concentration of 3.0 mg/ml in a buffered solution. Each sponge was infused with 1.5 ml of the rhBMP-2 solution.

30 The sponges were placed in the paraspinal bed directly on top of and bridging the two adjacent transverse processes. The sponges

- 17 -

were placed bilaterally, with two sponges (one on top of the other) on each side of the spine, resulting in a total dose of 9 mg rhBMP-2 per implant site. The animals were allowed to recover and move around ad libitum without restrictions during the study period.

5           The spines were manually assessed for fusion upon sacrifice (2, 4 and 6 months) and determined to be fused based upon the absence of motion during attempted bending, and presence of histological bridging bone.

10           The fusions were also evaluated by CT scan at 2, 4 and 6 months after implantation. FIGS. 1 and 2 show the CT scans for each subject studied. FIGS. 1 and 2 demonstrate the sequence of events that occur within the composite sponge carrier loaded with rhBMP-2. On the far left of the figures are three CT sections equally spaced throughout the fusion mass at 2 months post-operative, 15 showing that resorption of the composite sponge is just about complete due to the lack of radiopacity of the ceramic granules. The three middle CT sections show these same three CT sections at four months with increased bone deposition where the carrier once resided. The composite sponge has maintained the space within 20 the soft tissue site for a sufficient enough period of time for the desired volume of new bone deposition to occur. Finally, the far right three CT scans show even further bone deposition, remodeling and maturation with the formation of outer cortices around the periphery of the fusion masses by six months.

25

- 18 -

What is claimed is:

1. An osteogenic sponge composition useful for the induction of new bone growth in a mammal, comprising:

- 5           a resorbable sponge matrix material;  
          an osteogenic factor, said osteogenic factor incorporated in said sponge matrix material in an amount that causes an increased rate of resorption of said sponge matrix material in a mammal; and  
          particulate mineral having an average particle diameter of at  
10       least about 0.5 mm embedded in said resorbable sponge matrix material, said particulate mineral present in a weight ratio of at least 4:1 relative to said resorbable sponge matrix material, so as to provide a scaffold for bone ingrowth in the presence of said osteogenic factor.

15

2. The osteogenic sponge composition of claim 1, wherein said particulate mineral is present in a weight ratio of at least about 10:1 relative to said resorbable sponge matrix material.

- 20       3. The osteogenic sponge composition of claim 1, wherein said osteogenic factor comprises a bone morphogenetic protein, a LIM mineralization protein, or a nucleotide sequence encoding a bone morphogenetic protein or a LIM mineralization protein.

- 25       4. The osteogenic sponge composition of claim 1, wherein said resorbable sponge matrix material includes collagen.

5. The osteogenic sponge composition of claim 3, wherein said resorbable sponge matrix material includes collagen.

30

- 19 -

6. The osteogenic sponge composition of claim 1, wherein said particulate mineral is selected from the group consisting of bone particles and biocompatible synthetic calcium phosphate ceramics.

5        7. The osteogenic sponge composition of claim 6, wherein said particulate mineral comprises biphasic calcium phosphate.

8. The osteogenic sponge composition of claim 7, wherein said biphasic calcium phosphate has a porosity of at least about 50%.

10

9. The osteogenic sponge composition of claim 8, wherein said particulate mineral includes bone particles.

10. The osteogenic sponge composition of claim 9, wherein  
15        said bone particles are cortical bone particles.

11. The osteogenic sponge composition of claim 1, which is comprised at least about 95% by weight of said particulate mineral.

20        12. The osteogenic sponge composition of claim 1, wherein said particulate mineral has an average particle size in the range of about 0.5 mm to about 5.0 mm.

13. The osteogenic sponge composition of claim 1, wherein  
25        said porous particulate mineral has an average particle size in the range of about 1 to about 2 mm.

14. The osteogenic sponge composition of claim 1, wherein said osteogenic factor is a bone morphogenetic protein.

30

- 20 -

15. The osteogenic sponge composition of claim 14, wherein said bone morphogenetic protein is a recombinant human protein.

16. The osteogenic sponge composition of claim 15, wherein  
5 said bone morphogenetic protein is BMP-2 or BMP-7.

17. The osteogenic sponge composition of claim 16, further comprising an osteogenic enhancing factor selected from the group consisting of autographic bone marrow, allographic bone marrow,  
10 transforming growth factor- $\beta$ , fibroblast growth factor, platelet-derived growth factor, insulin-like growth factor, microglobulin- $\beta$ , and steroids.

18. An osteogenic sponge composition effective for the  
15 induction of new bone growth in a primate, comprising:

a resorbable sponge matrix material;

an osteogenic factor that stimulates osteoblasts and osteoclasts, said osteogenic factor incorporated in said sponge matrix material in an amount that causes an increased rate of resorption of said  
20 sponge matrix material in the primate; and

particulate mineral having an average particle diameter of at least about 0.5 mm embedded in said resorbable sponge matrix material, said particulate mineral present in a weight ratio of at least 4:1 relative to said resorbable sponge matrix material, so as to  
25 provide a mineral scaffold for a duration sufficient for osteoid ingrowth through an area in which said sponge composition is implanted.

19. The sponge composition of claim 18 wherein the primate  
30 is a human.

- 21 -

20. A method for inducing bone growth in a primate, comprising:

(a) providing an osteogenic sponge composition comprising:

5 a resorbable sponge matrix material;

an osteogenic factor that stimulates osteoblasts and osteoclasts, said osteogenic factor incorporated in said sponge matrix material in an amount that causes an increased rate of resorption of said sponge matrix material in the primate; and

10 particulate mineral having an average particle diameter of at least about 0.5 mm embedded in said resorbable sponge matrix material, said particulate mineral present in a weight ratio of at least 4:1 relative to said resorbable sponge matrix material, so as to provide a scaffold for bone ingrowth in the presence of said  
15 osteogenic factor; and

(b) implanting said osteogenic sponge composition in an area in which bone growth is desired in the primate, said osteogenic sponge composition providing a scaffold for a duration sufficient for osteoid ingrowth through an area in which said osteogenic sponge  
20 composition is implanted.

21. The method of claim 20, wherein said particulate mineral is present in a weight ratio of at least 10:1 relative to said resorbable sponge matrix material.

25

22. The method of claim 21, wherein said osteogenic factor comprises a bone morphogenetic protein, a LIM mineralization protein, or a nucleotide sequence encoding a bone morphogenetic protein or LIM mineralization protein.

30

- 22 -

23. The method of claim 20, wherein said resorbable sponge matrix material includes collagen.

24. The method of claim 22, wherein said resorbable sponge matrix material includes collagen.

25. The method of claim 20, wherein said particulate mineral is selected from the group consisting bone, a synthetic biocompatible calcium phosphate ceramic, or a mixture thereof.

10

26. The method of claim 25, wherein said porous particulate mineral comprises biphasic calcium phosphate.

27. The method of claim 26, wherein said biphasic calcium phosphate has a porosity of at least about 50%.

15

28. The method of claim 20, wherein said particulate mineral includes bone particles.

29. The method of claim 28, wherein said bone particles are cortical bone particles.

20

30. The method of claim 20, wherein said osteoinductive sponge composition is comprised at least about 95% by weight of said particulate mineral.

25

31. The method of claim 20, wherein said particulate mineral has an average particle size of about 0.5 mm to about 5.0 mm.



- 23 -

32. The method of claim 20, wherein said porous particulate mineral has an average particle size of about 1 to about 2 mm.

33. The method of claim 20, wherein said osteogenic factor is  
5 a bone morphogenetic protein.

34. The method of claim 33, wherein said bone morphogenetic protein is a recombinant human protein.

10 35. The method of claim 33, wherein said bone morphogenetic protein is BMP-2 or BMP-7.

36. The method of claim 20, wherein the primate is a human.

15 37. The method of claim 20, wherein the area is in the spine of said primate.

38. The method of claim 37, wherein the bone growth is induced to attain a spinal fusion.

20

39. The method of claim 38, wherein the spinal fusion is an interbody spinal fusion.

40. The method of claim 38, wherein the spinal fusion is a  
25 posterolateral spinal fusion.

41. The method of claim 38, wherein the spinal fusion includes a fusion between transverse processes of adjacent vertebrae.

- 24 -

42. An osteogenic sponge composition for the induction of new bone growth in a primate, comprising:

a carrier consisting essentially of a resorbable sponge matrix with particulate mineral embedded in said resorbable sponge matrix, said particulate mineral present in an amount constituting  
5 at least about 95% by weight of said carrier; and  
an osteogenic factor.

43. A highly mineralized sponge implant device consisting  
10 essentially of a resorbable sponge matrix formed of collagen and having particulate biocompatible mineral embedded within said matrix, said device comprised 1% to 3% by weight of the collagen and 97% to 99% by weight of the particulate biocompatible mineral.

15 44. The device of claim 42 wherein the particulate biocompatible mineral comprises bone particles.

45. The device of claim 42 wherein the particulate biocompatible mineral includes a synthetic ceramic.

20

46. The device of claim 44 wherein the ceramic material includes a calcium phosphate ceramic.

47. The device of claim 45 wherein the calcium phosphate  
25 ceramic is biphasic calcium phosphate.

- 25 -

48. An osteogenic implant, comprising:


a resorbable matrix carrier comprised 1% to 3% by weight of collagen in sponge form and 97% to 99% by weight of a particulate  
5 biocompatible mineral embedded within said collagen; and  
an osteogenic factor.

49. An interbody spinal fusion device, comprising:

a load bearing member sized for insertion between adjacent  
10 vertebrae; and  
a composition according to any of claims 1-19 and 42-48  
retained by said load bearing member.

50. A method for interbody spinal fusion in a mammal,

15 comprising implanting between adjacent vertebrae in the mammal  
an interbody spinal fusion device according to claim 49.



**Fig 1**




Fig. 2

# INTERNATIONAL SEARCH REPORT

In: International Application No  
PCT/US 00/03043

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61L27/22 A61L27/56 A61L27/46 A61K38/18

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61L A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| X          | EP 0 309 241 A (COLLAGEN CORP)<br>29 March 1989 (1989-03-29)<br>claims; examples   | 1-50                  |
| X          | WO 97 31661 A (LINDHOLM T SAM ;MATTINEN<br>AULIS (FI)) 4 September 1997 (1997-09-04)<br>claims; examples                               | 1-50                  |
| X          | US 5 001 169 A (NATHAN RANGA ET AL)<br>19 March 1991 (1991-03-19)<br>column 6, line 17 - line 68<br>column 7, line 1 - line 17; claims | 1-50                  |
| X          | WO 96 39203 A (BIOCOLL LAB INC)<br>12 December 1996 (1996-12-12)<br>claims   | 1-50                  |
| -/-        |  |                       |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

22 May 2000

Date of mailing of the international search report

07/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

ESPINOSA, M

# INTERNATIONAL SEARCH REPORT

In ternational Application No  
PCT/US 00/03043

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT |   |                       |
|--|---|-----------------------|
| Category *   | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
| X  | WO 97 40137 A (MUSCHLER GEORGE F ;OSIRIS<br>THERAPEUTICS INC (US); BRUDER SCOTT P (U)<br>30 October 1997 (1997-10-30)<br>claims | 1-50                  |
| X  | WO 98 17330 A (SDGI HOLDINGS INC ;MCKAY<br>WILLIAM F (US)) 30 April 1998 (1998-04-30)<br>claims                                 | 1-50                  |
| X  | WO 89 04646 A (JEFFERIES STEVEN R)<br>1 June 1989 (1989-06-01)<br>claims  | 1-50                  |
| A  | EP 0 530 804 A (SHAW ROBERT F)<br>10 March 1993 (1993-03-10)<br>claims  | 1-50                  |
| A  | US 5 785 710 A (MICHELSON GARY KARLIN)<br>28 July 1998 (1998-07-28)<br>cited in the application                                 |                       |

## INTERNATIONAL SEARCH REPORT

...international application No.

PCT/US 00/03043

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

In International Application No

PCT/US 00/03043

| Patent document<br>cited in search report |   | Publication<br>date | Patent family<br>member(s)   | Publication<br>date  |
|---|---|---------------------|--|--|
| EP 0309241                                | A | 29-03-1989          | US 4888366 A<br>AT 98879 T<br>AU 2275188 A<br>CA 1335177 A<br>DE 3886493 D<br>DE 3886493 T<br>ES 2060656 T<br>JP 1158964 A<br>JP 5053139 B                                 | 19-12-1989<br>15-01-1994<br>06-04-1989<br>11-04-1995<br>03-02-1994<br>14-04-1994<br>01-12-1994<br>22-06-1989<br>09-08-1993                             |
| WO 9731661                                | A | 04-09-1997          | AU 4721696 A<br>EP 0883410 A<br>FI 981818 A  | 16-09-1997<br>16-12-1998<br>12-10-1998   |
| US 5001169                                | A | 19-03-1991          | US 4563350 A<br>AT 54830 T<br>AU 585268 B<br>AU 4900585 A<br>CA 1266613 A<br>DE 3578874 D<br>EP 0182483 A<br>JP 1855544 C<br>JP 5055149 B<br>JP 62016421 A<br>US 4888366 A | 07-01-1986<br>15-08-1990<br>15-06-1989<br>01-05-1986<br>13-03-1990<br>30-08-1990<br>28-05-1986<br>07-07-1994<br>16-08-1993<br>24-01-1987<br>19-12-1989 |
| WO 9639203                                | A | 12-12-1996          | AU 6107496 A<br>CA 2222626 A<br>CN 1192700 A<br>EP 0851772 A   | 24-12-1996<br>12-12-1996<br>09-09-1998<br>08-07-1998   |
| WO 9740137                                | A | 30-10-1997          | AU 2462297 A<br>CA 2251983 A<br>EP 0906415 A   | 12-11-1997<br>30-10-1997<br>07-04-1999   |
| WO 9817330                                | A | 30-04-1998          | AU 4985197 A<br>EP 0934087 A   | 15-05-1998<br>11-08-1999   |
| WO 8904646                                | A | 01-06-1989          | CA 1339083 A<br>US 5904718 A   | 29-07-1997<br>18-05-1999   |
| EP 0530804                                | A | 10-03-1993          | US 5270300 A<br>AU 657888 B<br>AU 2541192 A<br>CA 2116859 A<br>IL 102988 A<br>JP 7500741 T<br>NO 940764 A<br>NZ 244060 A<br>WO 9304710 A<br>ZA 9206729 A                   | 14-12-1993<br>23-03-1995<br>05-04-1993<br>18-03-1993<br>08-02-1998<br>26-01-1995<br>29-04-1994<br>27-07-1997<br>18-03-1993<br>12-03-1993               |
| US 5785710                                | A | 28-07-1998          | US 5593409 A<br>US 5741253 A<br>US 5015247 A<br>AU 716409 B<br>AU 4445196 A<br>CA 2168835 A  | 14-01-1997<br>21-04-1998<br>14-05-1991<br>24-02-2000<br>29-08-1996<br>30-04-1994   |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/03043

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| US 5785710 A                              |                     | CN 1134810 A               | 06-11-1996          |
|   |                     | EP 0732093 A               | 18-09-1996          |
|   |                     | JP 8266563 A               | 15-10-1996          |
|   |                     | TR 960846 A                | 21-10-1996          |
|   |                     | US 5505732 A               | 09-04-1996          |
|   |                     | US 5797909 A               | 25-08-1998          |
|   |                     | US 5484437 A               | 16-01-1996          |
|   |                     | US 5772661 A               | 30-06-1998          |
|   |                     | AT 169811 T                | 15-09-1998          |
|   |                     | AU 3838789 A               | 12-01-1990          |
|   |                     | CA 1332999 A               | 15-11-1994          |
|   |                     | DE 68928790 D              | 24-09-1998          |
|   |                     | DE 68928790 T              | 25-03-1999          |
|   |                     | EP 0419564 A               | 03-04-1991          |
|   |                     | EP 0712607 A               | 22-05-1996          |
|   |                     | WO 8912431 A               | 28-12-1989          |